Arnon Nagler, Chaim Sheba Medical Center, Tel-Aviv, Israel, explains comments on the importance of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). The prognosis of patients with AML is currently based on MRD detection. Patients that are MRD negative pre-transplant have a much lower relapse rate, which translates to better survival rates. Detection of MRD post-transplant is an indicator of relapse allowing for early intervention and treatment. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
